Up next

Autoplay

Evaluating the effect of diabetes drug liraglutide for Alzheimer’s disease

1 Views • 08/20/25
Share
Side Effects
Side Effects
Subscribers
0

At the 31st International Conference of Alzheimer’s Disease International (ADI), held in Budapest, Hungary, from April 21–24 2016, Doug Brown, PhD, from Alzheimer's Society, London, United Kingdom, discusses the clinical development of liraglutide, a glucagon-like peptide (GLP)-1 receptor agonist, for people with Alzheimer’s disease.

Show more
0 Comments sort Sort By

Up next

Autoplay